
Anna R Michmerhuizen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7710195/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ARe we there yet? Understanding androgen receptor signaling in breast cancer. Npj Breast Cancer, 2020, 6, 47.	5.2	57
2	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. Journal of Clinical Investigation, 2020, 130, 958-973.	8.2	53
3	PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Molecular Cancer Therapeutics, 2019, 18, 2063-2073.	4.1	38
4	Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers. Clinical Cancer Research, 2020, 26, 6568-6580.	7.0	30
5	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Frontiers in Endocrinology, 2020, 11, 35.	3.5	24
6	A Signature That May Be Predictive of Early Versus Late Recurrence After Radiation Treatment for Breast Cancer That May Inform the Biology of Early, Aggressive Recurrences. International Journal of Radiation Oncology Biology Physics, 2020, 108, 686-696.	0.8	11
7	RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes. JCI Insight, 2022, 7, .	5.0	9
8	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. Npj Breast Cancer, 2022, 8, 31.	5.2	7
9	Bcl-xL Inhibition Radiosensitizes <i>PIK3CA/PTEN</i> Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression. Cancer Research Communications, 2022, 2, 679-693.	1.7	3
10	Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. British Journal of Cancer, 2022, 127, 927-936.	6.4	1
11	Degrading AR-dependent cancers: Expanding the role of PROTACs. Neoplasia, 2020, 22, 533-535.	5.3	0